Loading...

ONCOTELIC THERAPEUTICS INC Capital Structure Changes 8-K Filing

NCTL

ONCOTELIC THERAPEUTICS INC

()

2026 8-K

Joint Development Agreement

Product Launch Announcement

Research Presentation

Financing Agreement

Stock Agreement Details

Milestone Amendment

Contract Amendment

Funding Agreement Completed

Debt Financing Agreement

Access to Research Tools

Investment Offering Details

Investor Presentation Update

Equity Offerings

Presentation Announcement

External Links:

On January 23, 2026, Oncotelic Therapeutics, Inc. entered into a financing agreement with Mast Hill Fund, issuing a convertible note worth $398,333.33, secured against company assets, with a 10% interest rate and maturity of one year.

AI Assistant

ONCOTELIC THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.